International Registry of Healthcare Workers Exposed to COVID-19 Patients (UNITY Global)
NCT04626076 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6808
Last updated 2023-04-04
Summary
The International Registry of Healthcare Workers Exposed to COVID-19 Patients (UNITY Global), is an international registry of approximately 10,000 healthcare workers in low- and middle-income countries experiencing increasing numbers of COVID-19 cases and commensurate increased exposure to the SARS-CoV-2 virus among their healthcare worker populations.
Conditions
- SARS-CoV Infection
- Covid19
Interventions
- OTHER
-
Comparative Observational Cohort Study
This is a comparative observational cohort study; therefore, no preventive interventions, visits or laboratory tests are mandated. Dosing and duration of potential prophylactic treatment is at the discretion of the institution and/or healthcare provider, in accordance with regular local practice. However, serology testing for SARS-CoV-2 antibodies will be offered to the first 50% of participating HCWs per country, at enrollment and at the last follow-up (i.e. at Week 12)
Sponsors & Collaborators
-
Bill and Melinda Gates Foundation
collaborator OTHER -
Parexel
collaborator INDUSTRY -
Certara
lead INDUSTRY
Principal Investigators
-
Roman Casciano, Masters · Certara
-
Craig Rayner, PharmD · Certara
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-08-03
- Primary Completion
- 2021-08-05
- Completion
- 2022-06-15
Countries
- Pakistan
Study Locations
More Related Trials
-
Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine
NCT05409261 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
L9LS in Women of Childbearing Potential in Mali
NCT07060508 ·Status: RECRUITING ·Phase: PHASE2
-
Study of COVID-19 Outbreak in Hospital Departments of Bamako, Mali
NCT04710316 ·Status: COMPLETED ·Phase: NA
-
Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India
NCT00486382 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite
NCT00121862 ·Status: COMPLETED ·Phase: PHASE2
-
High-Titer Neutralizing Plasma for West Nile Fever in Hospitalized Patients
NCT07094724 ·Status: RECRUITING ·Phase: PHASE2
-
COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey
NCT04470648 ·Status: COMPLETED
-
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
NCT04612972 ·Status: COMPLETED ·Phase: PHASE3
-
The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil
NCT02530697 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires
NCT01214876 ·Status: COMPLETED
-
Malaria Challenge in Healthy Volunteers
NCT01500980 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis
NCT00111514 ·Status: COMPLETED ·Phase: PHASE1
-
ELISA Validation of Hypersensitive Rapid Diagnostic Test Results for Detection of P. Falciparum
NCT03132402 ·Status: COMPLETED
-
Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis
NCT02080026 ·Status: COMPLETED ·Phase: NA
-
Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection
NCT02098590 ·Status: COMPLETED ·Phase: NA
-
Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
NCT03129646 ·Status: COMPLETED ·Phase: PHASE3
-
Host Response to Infection and Treatment in Lymphatic Filarial Disease in India
NCT00342576 ·Status: COMPLETED
-
A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant
NCT02925403 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
NCT00790998 ·Status: COMPLETED ·Phase: PHASE3
-
Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAP
NCT06881732 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis
NCT00604955 ·Status: COMPLETED ·Phase: PHASE4
-
Characterizing Humoral Immune Response to Mosquito Bites
NCT04478370 ·Status: COMPLETED ·Phase: NA
-
Assessment of Immunogenicity, Safety and Reactogenicity of a Booster Dose of Various COVID-19 Vaccine Platforms in Individuals Primed With Several Regimes.
NCT05812586 ·Status: UNKNOWN ·Phase: PHASE3
-
Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria
NCT03503058 ·Status: COMPLETED ·Phase: PHASE2
-
Testing a Biometric Identification System to Improve Malaria Vaccine Completion
NCT07261280 ·Status: RECRUITING ·Phase: NA